Biotechnology and cardiovascular medicine – a hazy past and bright future?

Biotechnology and cardiovascular medicine – a hazy past and bright future? Melinda Swann, Adam Raman, Michael KirchengastFrom such successful beginnings, the biotechnology sector has since gone on to have a rather hazy past, for which there are many plausible explanations. In March 2000, the sector was grossly overvalued and, since then, investors’ aversion to the area has flourished due to the perceived risk they felt they were taking. This has led to the growth of many biotechnology companies being stunted since access to capital has become more difficult – studies, especially long-term survival trials in cardiovascular medicine.